Celyad Oncology announces conference program for September 2021

MONT-SAINT-GUIBERT, Belgium, September 01, 2021– (BUSINESS WIRE) – Regulatory news:

Celyad Oncology SA (Brussels: CYAD) (Paris: CYAD) (NASDAQ: CYAD) (Euronext & Nasdaq: CYAD), a clinical-stage cancer-focused biotechnology company, today announced that the Company plans to participate in the following conferences in September 2021:

2021 Wells Fargo Virtual Healthcare Conference
Dates: from Thursday September 9 to Friday September 10, 2021
Presentation date: Thursday September 9
Time: 11:20 am ET / 5:20 pm CET
Presenter: Filippo Petti, CEO
A webcast link will be available on the Events Celyad Oncology section website.

HC Wainwright 23rd Annual Global Investment Conference
Dates: Monday September 13 to Wednesday September 15, 2021
Presentation: On request starting September 13, 7 a.m. ET / 1 p.m. CET
Presenter: Filippo Petti, CEO

Baird Virtual Global Healthcare Conference 2021
Dates: from Tuesday September 14 to Wednesday September 15, 2021
Presentation date: Tuesday September 14
Time: 3:45 p.m. ET / 9:45 p.m. CET
Presenter: Filippo Petti, CEO

About Celyad Oncology SA

Celyad Oncology SA is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor (CAR T) T cell therapies for cancer. The Company is developing a pipeline of candidates for allogeneic (ready-to-use) and autologous (personalized) CAR T cell therapy for the treatment of hematologic malignancies and solid tumors. Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium, and New York, NY. The Company has received funding from the Walloon Region (Belgium) to support the advancement of its CAR T cell therapy programs. For more information, please visit www.celyad.com.

Forward-looking statement

This press release may contain forward-looking statements, within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may include statements regarding: the safety and clinical activity of Celyad Oncology pipelines and the financial condition, results of operations and business prospects. Forward-looking statements may involve known and unknown risks and uncertainties which could cause the actual results, financial condition, performance or achievements of Celyad Oncology to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include the expected start date of the Phase 1 trial by the end of 2020, our development of additional allogeneic shRNA-based candidates of our CYAD-200 series into a clinical trial, as well as the duration and severity of the COVID-19 pandemic. and the government measures implemented to respond to them. A further list and description of these risks, uncertainties and other risks can be found in the documents and reports of the Securities and Exchange Commission (SEC) of Celyad Oncology, including in its annual report on Form 20-F filed with the SEC March 25, 2020. and subsequent filings and reports by Celyad Oncology. These forward-looking statements speak only as of the date of publication of this document and actual results of Celyad Oncology may differ materially from those expressed or implied by these forward-looking statements. Celyad Oncology expressly disclaims any obligation to update such forward-looking statements in this document to reflect any change in its expectations in this regard or any change in the events, conditions or circumstances upon which such statement is based, except as required by law. law or regulation.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20210831005110/en/


Investor and media contacts:

Sara zelkovic
Communication & Investor Relations Director
Celyad Oncology
[email protected]

Daniel Ferry
General manager
LifeSci Advisors, LLC
[email protected]

About Stephen Arrington

Check Also

Raider Volleyball wraps up non-conference action this weekend in Milwaukee

History links DAYTON – The Wright State volleyball team wraps up the non-conference game this …

Leave a Reply

Your email address will not be published. Required fields are marked *